JP2017519727A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519727A5
JP2017519727A5 JP2016566962A JP2016566962A JP2017519727A5 JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5 JP 2016566962 A JP2016566962 A JP 2016566962A JP 2016566962 A JP2016566962 A JP 2016566962A JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
thieno
triazolo
chlorophenyl
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/060200 external-priority patent/WO2015169951A1/en
Publication of JP2017519727A publication Critical patent/JP2017519727A/ja
Publication of JP2017519727A5 publication Critical patent/JP2017519727A5/ja
Pending legal-status Critical Current

Links

JP2016566962A 2014-05-08 2015-05-08 チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 Pending JP2017519727A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461990457P 2014-05-08 2014-05-08
US61/990,457 2014-05-08
US201462012048P 2014-06-13 2014-06-13
US62/012,048 2014-06-13
US201462080751P 2014-11-17 2014-11-17
US62/080,751 2014-11-17
US201462086400P 2014-12-02 2014-12-02
US62/086,400 2014-12-02
US201562150044P 2015-04-20 2015-04-20
US62/150,044 2015-04-20
PCT/EP2015/060200 WO2015169951A1 (en) 2014-05-08 2015-05-08 Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds

Publications (2)

Publication Number Publication Date
JP2017519727A JP2017519727A (ja) 2017-07-20
JP2017519727A5 true JP2017519727A5 (https=) 2018-06-14

Family

ID=53191652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566962A Pending JP2017519727A (ja) 2014-05-08 2015-05-08 チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法

Country Status (11)

Country Link
US (1) US9968619B2 (https=)
EP (1) EP3139959A1 (https=)
JP (1) JP2017519727A (https=)
KR (1) KR20170002610A (https=)
CN (1) CN106852120A (https=)
AU (1) AU2015257658A1 (https=)
BR (1) BR112016026046A8 (https=)
CA (1) CA2947970A1 (https=)
MX (1) MX2016014574A (https=)
RU (1) RU2016147946A (https=)
WO (1) WO2015169951A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
AR096837A1 (es) 2013-07-08 2016-02-03 Incyte Corp Heterociclos tricíclicos como inhibidores de proteínas bet
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
EP4118431A1 (de) * 2020-03-12 2023-01-18 Heinrich-Heine-Universität Düsseldorf Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR20240028420A (ko) 2021-06-08 2024-03-05 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항암 화합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
WO2001095912A1 (fr) 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2009084693A1 (ja) * 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2683734A1 (en) * 2011-03-10 2014-01-15 Institut National de la Sante et de la Recherche Medicale (INSERM) Atip3 and biologically active fragments thereof for use in the treatment of cancer
MX2014015986A (es) 2012-06-25 2016-02-11 Oncoethix Gmbh Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
JP2015522025A (ja) * 2012-06-27 2015-08-03 ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri コレステロール生合成阻害剤によるエストロゲン受容体βの誘発および癌の処置方法
CN104968334B (zh) 2012-09-28 2018-09-14 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
DK2903616T3 (da) * 2012-10-04 2018-01-29 Ab Science Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2015018523A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A novel bet-brd inhibitor for treatment of solid tumors

Similar Documents

Publication Publication Date Title
JP2017519727A5 (https=)
RU2016147946A (ru) Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений
JP2017529332A5 (https=)
RU2017100921A (ru) Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина
JP2013510123A5 (https=)
JP2012136540A5 (https=)
RU2014124184A (ru) Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
JP2013510124A5 (https=)
MD4779B1 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
JP2018501315A5 (https=)
JP2016529246A5 (https=)
JP2013529611A5 (https=)
JP2014518544A5 (https=)
RU2014105577A (ru) Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин
JP2016516067A5 (https=)
PH12020500327A1 (en) Macrocyclic mcl-1 inhibitors and methods of use
MX377635B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
JP2017517579A5 (https=)
JP2019512535A5 (https=)
JP2016523974A5 (https=)
JP2015504091A5 (https=)
JP2015504081A5 (https=)
FI3865484T3 (fi) Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
CO6612185A2 (es) Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos